Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 180239
                    [Title] => Clot-dissolving therapy stops ‘submassive PE’
                    [Summary] => INGELHEIM, Germany – Clinical trial results published last week in the New England Journal of Medicine demonstrated that the clot-dissolving agent alteplase (Actilyse tPA) can prevent the clinical deterioration of patients with submassive pulmonary embolism.


                    [DatePublished] => 2002-10-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 155682
                    [Title] => Clot-dissolving therapy improves heart patients
                    [Summary] => ATLANTA, Georgia – Administering the clot-dissolving drug alteplase (Actilyse, Boehringer Ingelheim) early during massive pulmonary embolism prevents the disease from worsening, a new clinical trial showed. 


Patients who benefited from the treatment had signs of right-heart strain at presentation. Their hearts were laboring to function despite the presence of clots obstructing the pulmonary arteries, but the patients appeared hemodynamically stable or they had normal blood pressure. 


                    [DatePublished] => 2002-04-01 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

ALTEPLASE

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 180239
                    [Title] => Clot-dissolving therapy stops ‘submassive PE’
                    [Summary] => INGELHEIM, Germany – Clinical trial results published last week in the New England Journal of Medicine demonstrated that the clot-dissolving agent alteplase (Actilyse tPA) can prevent the clinical deterioration of patients with submassive pulmonary embolism.


                    [DatePublished] => 2002-10-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 155682
                    [Title] => Clot-dissolving therapy improves heart patients
                    [Summary] => ATLANTA, Georgia – Administering the clot-dissolving drug alteplase (Actilyse, Boehringer Ingelheim) early during massive pulmonary embolism prevents the disease from worsening, a new clinical trial showed. 


Patients who benefited from the treatment had signs of right-heart strain at presentation. Their hearts were laboring to function despite the presence of clots obstructing the pulmonary arteries, but the patients appeared hemodynamically stable or they had normal blood pressure. 


                    [DatePublished] => 2002-04-01 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Clot-dissolving therapy stops ‘submassive PE’

October 17, 2002 - 12:00am

INGELHEIM, Germany – Clinical trial results published last week in the New England Journal of Medicine demonstrated that the clot-dissolving agent alteplase (Actilyse tPA) can prevent the clinical deterioration...

Science and Environment

Clot-dissolving therapy improves heart patients

April 1, 2002 - 12:00am

ATLANTA, Georgia – Administering the clot-dissolving drug alteplase (Actilyse, Boehringer Ingelheim) early during massive pulmonary embolism prevents the disease from worsening, a new clinical trial showed....

Science and Environment